HOW TO OVERCOME THE EFFECTS OF "HYPERGLYCEMIC" MEMORY?
- Авторлар: Biryukova E.V.1, V Biryukova Y.1
-
Мекемелер:
- Шығарылым: № 3 (2012)
- Беттер: 58-62
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/279293
- ID: 279293
Дәйексөз келтіру
Толық мәтін
Аннотация
The article considers the questions of pathogenetic therapy of diabetic polyneuropathy. Pharmacological characteristics of thiamine and its fat-soluble analogue benfotiamine are discussed. Particular attention is paid to mechanisms of action of benfotiamine from a perspective of "hyperglycemic" memory. The results of clinical evaluation of efficacy and safety of benfotiamine are presented. By the example of Milgamma compositum (benfotiamine+pyridoxine) and Milgamma (B1, B6 and B12), high clinical efficacy of a combination of B vitamins is shown; potentials for their administration for the treatment of diabetics depending on the clinical course of distal polyneuropathy are discussed.
Негізгі сөздер
Әдебиет тізімі
- Boulton AJM, Vinik AI, Arezzo JC, et al. Diabetic neuropathy. A statement by the American Diabetes Association. Diabetes Care 2005;28:956-62.
- Kempler P. Neuropathies. Pathomechanism, clinical presentation, diagnosis, therapy. Budapest: Springer Scientific Publisher, 2002.
- Said G. Diabetic Neuropathy. A Review. Nat Clin Pract Neurol 2007;3(6):331-40.
- DCCT: The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
- Ihnat MA, Thorpe JE, Ceriello A. The "metabolic memory", the new challenge of diabetes. Diabet Med 2007;24:582-86.
- Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes 2005;54:1615-25.
- Russell JW, Feldman EL. Impaired glucose tolerance - does it cause neuropathy? Muscle Nerve 2001;24:1109-12.
- Herman WH, Kennedy L. for the GOAL A1c study. Underdiagnosis of peripheral neuropathy in type 2 diabetes. Diabetes Care 2005;28:1480-81.
- Happich M, John J, Stamenitis S, Clouth J, Polnau D. The quality of life and economic burden of neuropathy in diabetic patients in Germany in 2002 - results from the Diabetic Microvascular Complications (DIMICO) study. Diabetes Res Clin Pract 2008;81:223-30.
- Boulton AJM, Vileikyte L, Ragnarson-Tennwall G, Apelqvist J. The global burden of diabetic foot disease. Lancet 2005a; 366: 1719-24.
- Ziegler D. Treatment of diabetic neuropathy and neuropathic pain: how far have we come? Diabetes Care 2008;31:255-61.
- EDIC: The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensivetherapy on microvascular complications of type 1 diabetes mellitus. J Am Med Assoc 2002;287:2563-69.
- Marshall S, Flyvbjerg A. Prevention and early detection of vascular complications of diabetes. Brit Med J 2006;333:475-80.
- Tesfaye S, Stevens LK, Stephenson JM, et al. for the EURODIAB IDDM Study Group. Prevalence of diabetic peripheral neuropathy and its relation to glycemic control and potential risk factors: the EURODIAB IDDM complications study. Diabetologia 1996;39:1377-84.
- Mooney S, Leuendorf J-E, Hendrickson C, Hellmann H. Vitaminus thiamine derivatives after oral administration. Int J Clin Pharmacol Ther 1998; 36:216-21.
- Jermendy G. For Benfotiamine Trial: Use of benfotiamine for treating diabetic polyneuropathy (Hungarian multicenter trial). Hung Arch Int Med 1996;4:223-26.
- Hammes HP, Du X, Edelstein D et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003;9:294-99.
- Bitsch R, Wolf M, Möller J, et al. Bioavailability assessment of the lipophilic benfotiamine as compared to a water-soluble thiamine derivative. Ann Nutr Metab 1991;35:292-96.
- Thornalley PJ, Babaei-Jadidi R, Al Ali H et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia 2007;50:2164-70.
- Strake H, Lindenmann A, Federlin KA. A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diabetes 1996;104:311-16.
- Marchetti V, Menghini R, Rizza S, et al. Benfotiamine counteracts glucose toxicity effects on endothelial progenitor cell differentiation via Akt/FoxO signaling. Diabetes 2006;55:2231-37.
- Avena R, Arora S, Carmody BJ, et al. Thiamine (vitamin B1) protects against glucose- and insulin-medicated proliferation of human infragenicular arterial smooth muscle cells. Ann Vasc Surg 2000;14(1):37-43.
- Beltramo E, Berrone E, Buttiglieri S, Porta M. Thiamine and benfotiamine prevent increased apoptosis in endothelial cells and pericytes cultured in high glucose. Diabetes Metab Res Rev 2004;20:330-6.
- Haupt E, Ledermann H, Köpcke W. Benfotiamine in the treatment of diabetic polyneuropathy - a three-week randomized controlled pilot-study (BEDIP study). Int J Clin Pharmacol Ther 2005;43:71-7.
- Stracke H, Gaus W, Achenbach U, Federlin K, et al. Benfotiamine in Diabetic Polyneuropathy (BENDIP): Results of a randomised, double-blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes 2008;116:600-5.
- Simeonov S, Pavlova M, Mitkov M, et al. Therapeutic efficacy of "Milgamma" in patients with painful diabetic neuropathy. Folia Med (Plovdiv) 1997;39(4):5-10.
- Solomon LR. Disorders of cobalamin (vitamin B12) metabolism: emerging concept in patophysiology, diagnosis and treatment. Blood Rev 2007;21:113-30.
- Rabbani N, Shahzad Alam S, Riaz, et al. High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a pilot randomized, double-blind placebo-controlled study. Diabetologia 2009;52:208-12.
- Stirban A, Negrean M, Stratmann B, et al. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006;29(9):2064-71.
Қосымша файлдар
